Cancer News

News

Utica Native Kevin Byrd advocacy work honored and entered into Congressional Record | PRLog
www.prlog.org | Feb 11, 2012
Utica Native Kevin Byrd advocacy work honored and entered into Congressional Record. Utica Native Kevin Byrd Youngest Prostate Cancer Advocate in U.S. and New Health & Wellness Chairman for the 100 work is honored by Congressional Record Honoring February 2, 2012 Prostate Cancer Awareness

Eisai Company Ltd s Cancer Drug Reverses
www.biospace.com | Feb 10, 2012
In what is seen as a major breakthrough in finding a cure for Alzheimer's, neuroscientists at Case Western Reserve University School of Medicine, Ohio,

Roche Holding's CEO Discusses Q4 2011 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com | Feb 10, 2012
< p > Roche Holding Ltd. ( < a href='http://seekingalpha.com/symbol/rhhby.pk' title='Roche Hldg Ltd Spons' > RHHBY.PK < /a > ) < /p > < p > Q4 2011 Earnings Call < /p > < p > February 01, 2012 01:00 am ET < /p > < p > < strong > Executives < /strong > < /p > < p > Severin Schwan – Chief Executive

amednews: Cancer screening rates lower for Asians and Hispanics than other groups :: Feb. 10, 2012
www.ama-assn.org | Feb 10, 2012
Forty-seven percent received colorectal cancer screening in 2010 compared with 60% of whites, data show. Disparities also exist in testing for breast and cervical cancers.

UPenn sues Memorial Sloan-Kettering president for $1B over alleged stolen research -
www.fiercehealthcare.com | Feb 7, 2012
The President of Memorial Sloan-Kettering Cancer Center is facing a more than $1 billion lawsuit from the cancer center at the University of Pennsylvania--his former employer--over what the latter Read more...

MabCure, Biotech Investment Co | MabCure signs license agreement with Biotech Investment Corp |
www.pharmaasia.com | Feb 7, 2012
MabCure has signed a license agreement with Biotech Investment Corp. (Biotech), a Nevada-based biotechnology investment company. The agreement is an exclusive worldwide license to certain MabCure hybridoma clones producing antibodies against prostate cancer. In addition to the license fee paid to

PSA velocity a better cancer predictor | 6minutes
www.6minutes.com.au | Feb 3, 2012
Using PSA velocity improves the predictive capability for prostate cancer, a US study has shown.

How Does A Heart Know When It's Big Enough - 03/25/2010
www.hopkinsmedicine.org | Jan 27, 2012
A protein discovered in fruit fly eyes has brought a Johns Hopkins team closer to understanding how the human heart and other organs automatically "right size" themselves, a piece of information that may hold clues to controlling cancer.

Relatively lenient regulations regarding human subjects protections in the 1950s played an...
www.bioethicsinstitute.org | Jan 27, 2012
Relatively lenient regulations regarding human subjects protections in the 1950s played an important role in pediatric oncology being the first field of medicine in which doctors simultaneously treated patients and carried out clinical research, according to a pediatric hematologist-oncologist at

Anti-Prostate Cancer Agent Orteronel(TAK-700) Enters into Phase III Clinical Trials in Japan
www.takeda.com | Jan 27, 2012
Osaka, Japan, Cambridge, Mass and Tokyo, Japan, January 27, 2012 – Takeda Pharmaceutical Company Limited (“Takeda”) and Millennium: The Takeda Oncology Company (“Millennium”) today announced that Takeda Bio Development Center Limited (“Takeda Bio”) has initiated enrollment of patients in Japan for